Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				15 to 65				Other				GMALL01 NCT00198991


2.		German Multicenter Trial for the Treatment of Newly Diagnosed T-Lymphoblastic Lymphoma in Adults

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				15 to 65				Other				GMALL04 NCT00199017

Last Modified: 4/28/2008 First Published: 5/21/2007


3.		Phase II/III Randomized Study of Therapy Optimization Comprising Induction, Consolidation, and Intensification Regimens Followed By CNS Radiotherapy and Maintenance Therapy Comprising Thioguanine and Cytarabine in Pediatric Patients With Standard-Risk or High-Risk Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and under				Other				UCHM-AML-BFM-2004 UCHM-BfArM 4022064, NCT00111345, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004

Last Modified: 10/1/2008 First Published: 9/30/2008


4.		Phase I/II Study of Vorinostat, Cladribine, and Rituximab in Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 to 85				NCI, Pharmaceutical / Industry				OHSU-4180 4180, OHSU-HEM-08002-L, MERCK-OHSU-4180, NCT00764517


5.		Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				CAI NCT00126321


6.		2CDA With Rituximab in Hairy Cell Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				2004-0223 NCT00412594


7.		A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				CST1571AU235 / Komrokji CST1571AUS235, NCT00594555


8.		Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				AGMT_MALT EudraCT 2008-000767-41, NCT00656812


9.		Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				Other				2005-0733 NCT00492050

First Published: 11/18/2005


10.		Phase I Study of Cladribine, Cytarabine, and Imatinib Mesylate in Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				URCC-U26403 URCC-RSRB-10427, NOVARTIS-CSTI571AUS161, NCT00258271

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute